References
Barta SK, Gong JZ, Porcu P. Brentuximab vedotin in the treatment of CD30+ PTCL. Blood 2019; 134: 2339–45.
Ragmanauskaite L, Brahmbhatt M, Cheeley JT. Drug rash with eosinophilia and systemic symptoms related to Brentuximab vedotin: a report of 2 cases. JAAD Case Rep 2020; 6: 1119–22.
Mansoor N, McKenna L, Molloy O, et al. Emergence of lymphomatoid papulosis during treatment with Brentuximab vedotin. Int J Dermatol 2020; 59: e332–4.
van de Donk NW, Dhimolea E. Brentuximab vedotin. MAbs 2012; 4: 458–65.
Canal-Garcia E, Alamon-Reig F, Combalia A. Diffuse alopecia areata induced by Brentuximab vedotin therapy for advanced stage mycosis fungoides. Dermatol Ther 2022; 35: e15427.
Seong GH, Yun DK, Shon U, et al. A case of pityriasis lichenoides et varioliformis acuta-like eruption developed after pembrolizumab treatment for invasive thymoma. Ann Dermatol 2021; 33: 94–6.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest: none.
Additional information
Financial support: none.
About this article
Cite this article
Iinuma, S., Kobayashi, T. & Ishida-Yamamoto, A. Pityriasis lichenoides et varioliformis acuta-like eruption after brentuximab vedotin treatment for peripheral T-cell lymphoma. Eur J Dermatol 33, 316–317 (2023). https://doi.org/10.1684/ejd.2023.4494
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2023.4494